Advanced search
Publication Cover
Expert Opinion on Biological Therapy Volume 16, 2016 - Issue 4
Submit an article Journal homepage
964
Views
14
CrossRef citations to date
0
Altmetric
Drug Evaluations

Tocilizumab for treating juvenile idiopathic arthritis

Jessica L. TurnierDivision of Rheumatology, Department of Pediatrics, Cincinnati Children’s Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, OH, USA
&
Hermine I. BrunnerDivision of Rheumatology, Department of Pediatrics, Cincinnati Children’s Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, OH, USACorrespondence[email protected]
Pages 559-566 | Received 13 Dec 2015, Accepted 02 Feb 2016, Published online: 27 Feb 2016

Citations (14)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Frideriki Poutoglidou, Chryssa Pourzitaki, Maria Eleni Manthou, Efthimios Samoladas, Athanasios Saitis, Foteini Malliou & Dimitrios Kouvelas. (2022) The inhibitory effect of tocilizumab on systemic bone loss and tendon inflammation in a juvenile Collagen-Induced arthritis rat model. Connective Tissue Research 63:6, pages 577-589.
Read now
Melissa Y. Yeung, Steven Gabardi & Mohamed H. Sayegh. (2017) Use of polyclonal/monoclonal antibody therapies in transplantation. Expert Opinion on Biological Therapy 17:3, pages 339-352.
Read now

Articles from other publishers (12)

Theodoros-Ioannis Papadimitriou, Arjan van Caam, Peter M. van der Kraan & Rogier M. Thurlings. (2022) Therapeutic Options for Systemic Sclerosis: Current and Future Perspectives in Tackling Immune-Mediated Fibrosis. Biomedicines 10:2, pages 316.
Crossref
Mohammed A. Muzaffer & Abobakr A. Abdelgalil. (2021) Tocilizumab in management of refractory juvenile idiopathic arthritis, 10 years of experience at tertiary university hospital. Egyptian Rheumatology and Rehabilitation 48:1.
Crossref
Bogna Grygiel-Górniak, Osama Shaikh, Nikita Niranjan Kumar, Shao Heng Hsu & Włodzimierz Samborski. (2021) Use of the rheumatic drug tocilizumab for treatment of SARS-CoV-2 patients. Rheumatology 59:4, pages 252-259.
Crossref
Elnaz Roohi, Nematollah Jaafari & Farshad Hashemian. (2021) On inflammatory hypothesis of depression: what is the role of IL-6 in the middle of the chaos?. Journal of Neuroinflammation 18:1.
Crossref
Atreyee Borthakur, Yogamaya D Prabhu & Abilash Valsala Gopalakrishnan. (2020) Role of IL-6 signalling in Polycystic Ovarian Syndrome associated inflammation. Journal of Reproductive Immunology 141, pages 103155.
Crossref
David F. Boyd, Taylor L. Wilson & Paul G. Thomas. 2020. Immunopathology. Immunopathology 247 284 .
M. I. Kaleda, I. P. Nikishina & O. M. Kostareva. (2019) Optimization of systemic juvenile arthritis treatment regimens with correction of tocilizumab intravenous administration according to data of observational retrospective study. Rheumatology Science and Practice 57:2, pages 229-234.
Crossref
Justyna Roszkiewicz, Krzysztof Orczyk & Elżbieta Smolewska. (2018) Tocilizumab in the treatment of systemic-onset juvenile idiopathic arthritis – single-centre experience. Rheumatology 56:5, pages 279-284.
Crossref
Gloria C. Higgins. (2018) Complications of Treatments for Pediatric Rheumatic Diseases. Pediatric Clinics of North America 65:4, pages 827-854.
Crossref
Violetta Opoka-Winiarska, Zbigniew Żuber, Ekaterina Alexeeva, Vyacheslav Chasnyk, Irina Nikishina, Grażyna Dębowska & Elżbieta Smolewska. (2018) Long-term, interventional, open-label extension study evaluating the safety of tocilizumab treatment in patients with polyarticular-course juvenile idiopathic arthritis from Poland and Russia who completed the global, international CHERISH trial. Clinical Rheumatology 37:7, pages 1807-1816.
Crossref
Lisa M. Sedger, Charani Ranasinghe, Michael F. McDermott & Parisa Asvadi. 2017. Immunotherapy - Myths, Reality, Ideas, Future. Immunotherapy - Myths, Reality, Ideas, Future.
Patrizia Fasching, Martin Stradner, Winfried Graninger, Christian Dejaco & Johannes Fessler. (2017) Therapeutic Potential of Targeting the Th17/Treg Axis in Autoimmune Disorders. Molecules 22:1, pages 134.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.